Last month, the FDA approved Regeneron’s Otarmeni, a groundbreaking gene therapy for specific hearing loss, signaling a shift in focus from oncology to various neurodegenerative and cardiac diseases in gene therapy development. Notable companies like Eli Lilly, Lexeo Therapeutics, and Medera are advancing therapies targeting conditions such as Alzheimer’s, Parkinson’s, and cardiovascular issues. Meanwhile, challenges remain as seen with Sarepta Therapeutics’ DMD therapy, which faced scrutiny following adverse events, contrasted by positive Phase 3 results for REGENXBIO’s alternative DMD treatment. The gene therapy field continues to evolve with a focus on safer, more precise delivery systems for a range of conditions.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/drug-development/4-spaces-primed-for-the-next-wave-of-gene-therapies
